Background: Recent US guidelines lowered the threshold for diagnosing hypertension while other international guidelines use alternative/no labels for the same group (blood pressure [BP], <140/90 mm Hg). We investigated potential benefits and harms of hypertension and high-normal BP labels, compared with control, among people at lower risk of cardiovascular disease.
Methods: We conducted a randomized experiment using a national sample of Australians (n=1318) 40 to 50 years of age recruited from an online panel. Participants were randomized to 1 of 3 hypothetical scenarios where a general practitioner told them they had a BP reading of 135/85 mm Hg, using either hypertension/high-normal BP/control (general BP description) labels. Participants were then randomized to receive an additional absolute risk description or nothing. Primary outcomes were willingness to change diet and worry. Secondary outcomes included exercise/medication intentions, risk perceptions, and other psychosocial outcomes.
Results: There was no difference in willingness to change diet across label groups (=0.22). The hypertension label (mean difference [MD], 0.74 [95% CI, 0.41-1.06]; <0.001) and high-normal BP label (MD, 0.45 [95% CI, 0.12-0.78]; =0.008) had increased worry about cardiovascular disease risk compared with control. There was no evidence that either label increased willingness to exercise (=0.80). However, the hypertension (MD, 0.20 [95% CI, 0.04-0.36]; =0.014), but not high-normal label (MD, 0.06 [95% CI, -0.10 to 0.21]; =0.49), increased willingness to accept BP-lowering medication compared with control. Psychosocial differences including lower control, higher risk perceptions, and more negative affect were found for the hypertension and high-normal labels compared with control. Providing absolute risk information decreased willingness to change diet (MD, 0.25 [95% CI, 0.10-0.41]; =0.001) and increase exercise (MD, 0.28 [95% CI, 0.11-0.45]; =0.001) in the hypertension group.
Conclusions: Neither hypertension nor high-normal labels motivated participants to change their diet or exercise more than control, but both labels had adverse psychosocial outcomes. Labeling people with systolic BP of 130 to 140 mm Hg, who are otherwise at low risk of cardiovascular disease, may cause harms that outweigh benefit. Registration: URL: http://www.anzctr.org.au/; Unique identifier: ACTRN12618001700224.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCOUTCOMES.120.007160 | DOI Listing |
BMJ Oncol
December 2023
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Objectives: Non-mortality benefits of breast cancer screening are rarely considered in assessments of benefits versus harms. This study aims to estimate the rate of overdiagnosis in women with screen-detected breast cancer (SDBC) by allocating cases to either possibly overdiagnosed (POD) or not overdiagnosed categories and to compare treatment recommendations for surgery and adjuvant treatments by category, age at diagnosis and cancer stage.
Methods And Analysis: Retrospective secondary analysis of 10 191 women diagnosed with breast cancer in Australia and New Zealand in 2018.
ACS Appl Bio Mater
January 2025
Department of Materials Science and Engineering, and Centre for Functional Photonics (CFP), City University of Hong Kong, Hong Kong SAR 999077, P. R. China.
Bioimaging probes based on carbon dots (CDs) can become a useful replacement for existing commercial probes, benefiting clinical diagnostics. While the development of dual-mode CD-based probes for magnetic resonance imaging (MRI), which provides the ability for photoluminescence (PL) detection at the same time, is ongoing, several challenges have to be addressed. First, most of the CD-based probes still emit at shorter wavelengths (blue/green spectral range), which is harmful to biological objects or have very low PL intensity in the biological window of tissue transparency (red/near-infrared spectral range).
View Article and Find Full Text PDFJMIR Form Res
January 2025
Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Background: Opioid medications are important for pain management, but many patients progress to unsafe medication use. With few personalized and accessible behavioral treatment options to reduce potential opioid-related harm, new and innovative patient-centered approaches are urgently needed to fill this gap.
Objective: This study involved the first phase of co-designing a digital brief intervention to reduce the risk of opioid-related harm by investigating the lived experience of chronic noncancer pain (CNCP) in treatment-seeking patients, with a particular focus on opioid therapy experiences.
Personal Disord
January 2025
Department of Psychological Science, Kent State University.
Antagonism is a personality domain located in most major trait models and is central to multiple personality disorders. This construct has been linked to many societally harmful externalizing behaviors (e.g.
View Article and Find Full Text PDFJ Drug Target
January 2025
School of Stomatology, Wannan Medical College, Wuhu 241000, Anhui, China.
There are 275,000 new cases of oral cancer (OC) per year, making it the sixth most common cancer in the world. Severe adverse effects, including loss of function, deformity, and systemic toxicity, are familiar with traditional therapies such as radiation, chemotherapy, and surgery; due to their unique properties, nanoparticles (NPs) have emerged as a superior alternative over chemo/radiotherapy and surgery due to their targeting capability, bioavailability, compatibility, and high solubility. Due to their unique properties, metallic NPs have garnered significant attention in OC control.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!